Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AMG-329 by Amgen for Rheumatic Disorders: Likelihood of Approval
AMG-329 is under clinical development by Amgen and currently in Phase I for Rheumatic Disorders. According to GlobalData, Phase I...
Data Insights
AMG-329 by Amgen for Sicca Syndrome (Sjogren): Likelihood of Approval
AMG-329 is under clinical development by Amgen and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase...